Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
Open Access
- 25 October 2011
- journal article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 26 (5), 1081-1090
- https://doi.org/10.1038/leu.2011.290
Abstract
Angiogenesis is considered a hallmark of multiple myeloma (MM) progression. In the present study, we evaluated the morphological and functional features of endothelial cells (ECs) derived from bone marrow (BM) of patients affected by MM (MMECs). We found that MMECs compared with normal BM ECs (BMECs) showed increased expression of syndecan-1. Silencing of syndecan-1 expression by RNA interference technique decreased in vitro EC survival, proliferation and organization in capillary-like structures. In vivo, in severe combined immunodeficient mice, syndecan-1 silencing inhibited MMEC organization into patent vessels. When overexpressed in human umbilical vein ECs and BMECs, syndecan-1 induced in vitro and in vivo angiogenic effects. Flow-cytometric analysis of MMECs silenced for syndecan-1 expression indicated a decreased membrane expression of vascular endothelial growth factor (VEGF) receptor-2 (VEGFR-2). Immunoprecipitation and confocal analysis showed colocalization of VEGFR-2 with syndecan-1. Absence of nuclear translocation of VEGFR-2 in syndecan-1-knockdown cells together with the shift from perinuclear localization to recycling compartments suggest a role of syndecan-1 in modulation of VEGFR-2 localization. This correlated with an in vitro decreased VEGF-induced invasion and motility. These results suggest that syndecan-1 may contribute to the highly angiogenic phenotype of MMECs by promoting EC proliferation, survival and modulating VEGF–VEGFR-2 signalling.Keywords
This publication has 48 references indexed in Scilit:
- Syndecan-1 Is Required for Robust Growth, Vascularization, and Metastasis of Myeloma Tumors in VivoPublished by Elsevier BV ,2009
- PAX2 expression by HHV-8–infected endothelial cells induced a proangiogenic and proinvasive phenotypeBlood, 2008
- The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapyBlood, 2007
- Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myelomaBlood, 2006
- Angiogenesis in multiple myelomaEuropean Journal of Cancer, 2006
- The syndecan-1 ectodomain regulates αvβ3 integrin activity in human mammary carcinoma cellsThe Journal of cell biology, 2004
- Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathwaysBlood, 2004
- Syndecan-1 Expression on Malignant Cells from the Blood and Marrow of Patients with Plasma Cell Proliferative Disorders and B-Cell Chronic Lymphocytic LeukemiaLeukemia & Lymphoma, 1998
- A plasmocyte selective monoclonal antibody (B‐B4) recognizes syndecan‐1British Journal of Haematology, 1996
- Bone marrow angiogenesis and progression in multiple myelomaBritish Journal of Haematology, 1994